HK inno.N ships out 1st K-CAB batch to Mongolia

HK inno.N said that it recently shipped the first batch of K-CAB (ingredient: tegoprazan), a drug for gastroesophageal reflux disease (GERD), to Mongolia.

The shipment made Mongolia the second country among the company’s 34 overseas markets where HK inno.N plans to launch K-CAB. China is the first foreign country where the company launched K-CAB.

Monos Pharma, a Mongolian pharmaceutical company with more than 200 local drugstore chains, will be in charge of distributing K-CAB. HK inno.N signed an export contract with Monos in August 2020 and received local approval in October 2021.

Monos plans to release the drug in Mongolia next month.

HK inno.N said it expects K-CAB, the first P-CAB-based new drug introduced in the Mongolian market, to lead the generational change of gastroesophageal reflux disease drugs from the existing proton pump inhibitor (PPI)-based to P-CAB-based drugs.

"In the Mongolian market, digestive diseases have been the number one cause of disease over the past decade," an HK inno.N official said. "More than half of the Mongolian population is overweight or obese as people enjoy meat and alcohol. As obesity is one of the causes of gastroesophageal reflux disease, the market for gastroesophageal reflux disease treatment in Mongolia is expected to grow further.”

K-CAB became Korea's 30th novel drug in 2018. It is the first potassium-competitive acid blocker (P-CAB) to obtain the indication for EE(Erosive esophagitis) and NERD(Non-erosive reflux disease) GERD in Korea.

While conventional treatments, such as proton pump inhibitors (PPI), need three to five days to show efficacy, P-CAB drugs suppress gastric acid secretion in just one hour. In addition, p-CAB treatments inhibit excessive secretion of gastric acid during nighttime, reducing chest pain and sleep disorder.